Rosuvastatin Effect on Atherosclerotic Plaque Metabolism (ROPPET-NAF)
Rosuvastatin Effect on Atherosclerotic Plaque Metabolism - a Subclinical Atherosclerosis Imaging Study With 18F-NaF PET-CT
Sponsor: AstraZeneca
Listed as NCT03233243, this PHASE4 trial focuses on Atherosclerosis and Cardiovascular Diseases and remains completed. Sponsored by AstraZeneca, it has been updated 14 times since 2020, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Jun 2022 — Nov 2022 [monthly]
Recruiting PHASE4
-
Jan 2021 — Jun 2022 [monthly]
Recruiting PHASE4
▶ Show 9 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Apr 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE4
-
Nov 2019 — Apr 2020 [monthly]
Not Yet Recruiting PHASE4
-
May 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE4
-
Jun 2018 — May 2019 [monthly]
Not Yet Recruiting PHASE4
Phase: None → PHASE4
-
Apr 2018 — Jun 2018 [monthly]
Not Yet Recruiting
Phase: NA → None
-
Jan 2018 — Apr 2018 [monthly]
Not Yet Recruiting NA
Phase: PHASE4 → NA
-
Nov 2017 — Jan 2018 [monthly]
Not Yet Recruiting PHASE4
-
Aug 2017 — Nov 2017 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- University of Coimbra
For direct contact, visit the study record on ClinicalTrials.gov .